Record number:
246
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
Most recent risk assessment for breast cancer (Council of Europe, 2022):
Newly diagnosed invasive breast cancer is an unacceptable risk for organ donation. Organs from donors with invasive breast cancer might be accepted in selected cases after full treatment, complete remission and stringent follow-up for > 5 years, depending on the initial stage and E/P and HER2/neu receptor expression, always bearing in mind the risk of transmission due to possible late metastases. Breast cancer stage 1 (AJCC, 8th edition) [18] with curative surgery and cancer-free period > 5 years seems to be associated with low to intermediate risk for transmission. All other invasive breast cancer stages are considered high-risk for transmission, independent of the presumed recurrence-free survival and treatment.
Time to detection:
6 months
Alerting signals, symptoms, evidence of occurrence:
Osteolytic bone and central nervous system metastases due to ductal breast adenocarcinoma.
Demonstration of imputability or root cause:
Not specified, except for wife to husband donation. Imputed to be donor origin by type of tumour and resolution with graft rejection
Imputability grade:
3 Definite/Certain/Proven
Groups audience:
Suggest new keywords:
Registry series
Living donor
kidney transplant
ductal adenocarcinoma
Suggest references:
AAA
Expert comments for publication:
According to report, immunosuppression stopped, chemotherapy given. Graft lost and tumor resolved; attributed to tumor rejection but difficult to prove in the setting of chemotherapy. This is one case in this report from the UNOS database